Strategy Shares Gold Enhanced Yield ETF (GOLY) Cotización

BRO 1 MILLION SHARES DID DAMAGE??LMAO.IS THE CD THAT HATES TO SEE ANY SELLER.

Email got hacked unfortunately my twitter page has the new one.   Thanks PB 

Can we be all friends.  

I would like to know when sharp will tweet again and pull his head out of his ass. 

When we getting the supposed name and ticker change.  Nothing like the stock price bleeding down. As usual.  So frustrating 

If you did your homework, it was clear the company had impressive products; the fault in progress was with Gensler, and the price was actually rock bottom. If you didn’t this, then maybe you weren't watching?

🏆️ Filed a Form S-1 Registration Statement,
are offering shares of the Company's common stock to the public.
As soon as practicable after the effective date of this Registration Statement.

PROSPECTUS
All Things Mobile Analytic, Inc.
30,000,000 Share

KEYNOTE-D58 is a pivotal trial (N=741) of Optune concomitant with temozolomide plus keytruda in ndGBM. The estimated primary completion date is April 2029.

$ILLR Triller is the Majority owner of Bare Knuckle Fighting Championship (#BKFC).
This is just one major part of Triller!

1. Triller is Majority Owner of BKFC.
2. World Famous Conor McGregor is Part-Owner
3. $25 Million Tournament Coming up!
4. BKFC is the

$ILLR Triller is the Majority owner of Bare Knuckle Fighting Championship (#BKFC).
This is just one major part of Triller!

1. Triller is Majority Owner of BKFC.
2. World Famous Conor McGregor is Part-Owner
3. $25 Million Tournament Coming up!
4. BKFC is the

I can't wait for the PR explaining the need for 700 million more shares. Never ending source of entertainment

Gary,

I strongly suggest you go through the details of all the outcome measures adopted in the combo trial. They are so disruptive. I also think we should abandon the old concept about the definition of phase on clinical trials. The phase definition for DCVax-L doesn't matter. What it

Yep you did get it straight .
There is a reason companies apply to FDA and EMA . And there is reason for current SP.
But problem is that when given  straight to you , you can't comprehend straightforward reasons 

Very good opportunity

Nothing personal, but you reek of desperation for some reason. Longs will do great here.

Data from the PhII 2-THE-TOP trial https://www.onclive.com/view/temozolomide-pembrolizumab-plus-ttfields-leads-to-tumor-control-in-newly-diagnosed-glioblastoma

Yeah right 

Maybe you should double down, buy 10M shares...😎

Just watch out for these types of days..."1/3/25, Buy: 1,300,000, Neutral: 366,005, Sell: 66,963,117.😎

You'll be seeing more of them.

I would take your bet but you have the ethics of someone who would work for an idiot who would try to kill a cure for cancer. Thus, I would never trust you!

And someone to pay NWBO ( not advent ) for those treatments 

Are they really? That's evidence of a scam.

Dstocks, it's clear that many are interested in the kind of work we're doing. My question is, are any beyond the Phase 1/2 trials.

I believe we're clearly the leaders here and with approvals while it may make it easier for others, they'll still be many years before the can possibly g

Have you seen the stock price?

Enough said.

The stock price alone certainly isn't enough said.

SDCRBS, Please let me know if I can help you in any way. Just DM me. I'm sorry and sad to see all this CA and LA destruction.

I'm in the Houston area and couldn't imagine this type of destruction.

So Sorry.

I’ve learned so much from valuable contributors like Mr C and Dino and great respects for your researches and insights, then this kind of bickering just knock you off the pedestal into muck. Just respond with ‘next’ if you refuse to lower yourself into the mud. I have more respect for people like

Tic toc

Translational data from the PhI B-cell lymphomas trial demonstrated primary, secondary and tertiary tissue trafficking and clearance of CD19+ cells. That should help enable an immune reset in autoimmune diseases.

The next-gen CAR-T's will incorporate a suite of novel synthetic edits t